Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
$44.24
-0.1%
$46.93
$1.16
$14.10
$1.92B-0.12189,291 shs345,669 shs
Inhibrx, Inc. stock logo
INBX
Inhibrx
$11.71
+4.7%
$12.78
$10.80
$34.73
$169.51MN/A184,945 shs63,445 shs
Owens & Minor, Inc. stock logo
OMI
Owens & Minor
$7.16
+2.1%
$8.08
$6.07
$21.02
$552.76M1.381.12 million shs1.17 million shs
Patterson Companies, Inc. stock logo
PDCO
Patterson Companies
$31.33
$31.22
$19.45
$31.79
$2.77B0.731.24 million shsN/A
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
0.00%-10.64%+25.57%-19.14%+45.72%
Inhibrx, Inc. stock logo
INBX
Inhibrx
+4.74%-5.03%+0.86%-6.47%-65.85%
Owens & Minor, Inc. stock logo
OMI
Owens & Minor
+1.92%-11.72%+3.70%-15.00%-61.59%
Patterson Companies, Inc. stock logo
PDCO
Patterson Companies
0.00%0.00%+1.36%+0.97%+23.83%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Inhibrx, Inc. stock logo
INBX
Inhibrx
2.0546 of 5 stars
0.03.00.04.63.72.50.0
Owens & Minor, Inc. stock logo
OMI
Owens & Minor
4.7924 of 5 stars
3.02.00.03.92.63.33.8
Patterson Companies, Inc. stock logo
PDCO
Patterson Companies
1.9961 of 5 stars
1.03.02.51.70.01.72.5
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
0.00
N/AN/AN/A
Inhibrx, Inc. stock logo
INBX
Inhibrx
2.00
HoldN/AN/A
Owens & Minor, Inc. stock logo
OMI
Owens & Minor
2.00
Hold$12.5074.70% Upside
Patterson Companies, Inc. stock logo
PDCO
Patterson Companies
2.09
Hold$26.57-15.19% Downside

Current Analyst Ratings Breakdown

Latest OMI, PDCO, INBX, and GMTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/17/2025
Owens & Minor, Inc. stock logo
OMI
Owens & Minor
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$13.00 ➝ $11.00
3/10/2025
Owens & Minor, Inc. stock logo
OMI
Owens & Minor
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetUnderweight ➝ Underweight$14.00 ➝ $10.00
3/3/2025
Owens & Minor, Inc. stock logo
OMI
Owens & Minor
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$10.00 ➝ $11.00
2/25/2025
Owens & Minor, Inc. stock logo
OMI
Owens & Minor
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$14.00 ➝ $10.00
2/13/2025
Owens & Minor, Inc. stock logo
OMI
Owens & Minor
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$25.00 ➝ $13.00
(Data available from 5/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
N/AN/AN/AN/A$2.89 per shareN/A
Inhibrx, Inc. stock logo
INBX
Inhibrx
$200K847.57N/AN/AN/A
Owens & Minor, Inc. stock logo
OMI
Owens & Minor
$10.70B0.05$5.72 per share1.25$12.08 per share0.59
Patterson Companies, Inc. stock logo
PDCO
Patterson Companies
$6.51B0.43$3.42 per share9.17$11.18 per share2.80
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
-$71.87M-$1.00N/AN/AN/AN/A-38.78%-35.88%N/A
Inhibrx, Inc. stock logo
INBX
Inhibrx
-$154.96MN/A0.00N/AN/AN/A-113.74%-80.56%6/16/2025 (Estimated)
Owens & Minor, Inc. stock logo
OMI
Owens & Minor
-$41.30M-$4.75N/A4.070.20-0.46%14.60%2.51%8/1/2025 (Estimated)
Patterson Companies, Inc. stock logo
PDCO
Patterson Companies
$185.93M$1.5418.3212.842.712.37%19.77%6.66%6/17/2025 (Estimated)

Latest OMI, PDCO, INBX, and GMTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/10/2025Q1 2025
Owens & Minor, Inc. stock logo
OMI
Owens & Minor
$0.20$0.23+$0.03N/AN/AN/A
5/8/2025Q1 2025
Owens & Minor, Inc. stock logo
OMI
Owens & Minor
$0.20$0.23+$0.03-$0.32$2.66 billion$2.63 billion
3/17/2025Q4 2024
Inhibrx, Inc. stock logo
INBX
Inhibrx
-$2.88-$3.09-$0.21-$3.09N/A$0.10 million
2/28/2025Q4 2024
Owens & Minor, Inc. stock logo
OMI
Owens & Minor
$0.53$0.55+$0.02-$3.84$2.68 billion$2.70 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
N/AN/AN/AN/AN/A
Inhibrx, Inc. stock logo
INBX
Inhibrx
N/AN/AN/AN/AN/A
Owens & Minor, Inc. stock logo
OMI
Owens & Minor
N/AN/AN/AN/AN/A
Patterson Companies, Inc. stock logo
PDCO
Patterson Companies
$1.043.32%N/A67.53%N/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
N/A
71.49
71.49
Inhibrx, Inc. stock logo
INBX
Inhibrx
N/A
4.70
4.70
Owens & Minor, Inc. stock logo
OMI
Owens & Minor
2.11
1.09
0.45
Patterson Companies, Inc. stock logo
PDCO
Patterson Companies
0.34
1.37
0.76

Institutional Ownership

CompanyInstitutional Ownership
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
75.42%
Inhibrx, Inc. stock logo
INBX
Inhibrx
82.46%
Owens & Minor, Inc. stock logo
OMI
Owens & Minor
98.04%
Patterson Companies, Inc. stock logo
PDCO
Patterson Companies
85.43%

Insider Ownership

CompanyInsider Ownership
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
12.90%
Inhibrx, Inc. stock logo
INBX
Inhibrx
17.09%
Owens & Minor, Inc. stock logo
OMI
Owens & Minor
3.69%
Patterson Companies, Inc. stock logo
PDCO
Patterson Companies
1.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
3043.33 million37.74 millionNot Optionable
Inhibrx, Inc. stock logo
INBX
Inhibrx
16614.48 million11.26 millionOptionable
Owens & Minor, Inc. stock logo
OMI
Owens & Minor
22,50077.26 million74.34 millionOptionable
Patterson Companies, Inc. stock logo
PDCO
Patterson Companies
7,70088.47 million86.64 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Gemini Therapeutics stock logo

Gemini Therapeutics NASDAQ:GMTX

$44.24 -0.05 (-0.11%)
As of 05/9/2025

Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.

Inhibrx stock logo

Inhibrx NASDAQ:INBX

$11.71 +0.53 (+4.74%)
Closing price 05/12/2025 04:00 PM Eastern
Extended Trading
$11.72 +0.01 (+0.09%)
As of 04:20 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.

Owens & Minor stock logo

Owens & Minor NYSE:OMI

$7.16 +0.15 (+2.07%)
Closing price 05/12/2025 03:59 PM Eastern
Extended Trading
$7.32 +0.17 (+2.38%)
As of 04:53 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Owens & Minor, Inc. is a healthcare solutions company, which engages in the product manufacturing and delivery, home health supply, and perioperative services to support care through the hospital and into the home. It operates through the Products and Healthcare Services, and Patient Direct segments. The Products and Healthcare Services segment includes medical distribution, the outsourced logistics and value-added services business, and global products, which manufacture and source medical surgical products through the production and kitting operations. The Patient Direct segment includes the home healthcare business, Byram and Apria. The company was founded by Otho O. Owens and G. Gilmer Minor in 1882 and is headquartered in Henrico County, VA.

Patterson Companies stock logo

Patterson Companies NASDAQ:PDCO

$31.33 0.00 (0.00%)
As of 04/17/2025

Patterson Companies, Inc. engages in the distribution of dental and animal health products in the United States, the United Kingdom, and Canada. The company operates through three segments: Dental, Animal Health, and Corporate segments. The Dental segment offers consumable products, including infection control, restorative materials, and instruments; basic and advanced technology and dental equipment; practice optimization solutions, such as practice management software, e-commerce, revenue cycle management, patient engagement solutions, and clinical and patient education systems. It also provides a range of related services comprising software and design services, maintenance and repair, and equipment financing. The Animal Health segment distributes biologicals, pharmaceuticals, vaccines, parasiticides, diagnostics, prescription and non-prescription diets, nutritional's, consumable supplies, equipment, and software, as well as value-added services. This segment also provides private label portfolio of products to veterinarians, producers, and retailers under the Aspen, First Companion, and Patterson Veterinary brands. The Corporate segment offers customer financing services; and sells other miscellaneous products. It serves dentists, laboratories, institutions, other healthcare professionals, veterinarians, other animal health professionals, production animal operators, and animal health product retailers. The company was formerly known as Patterson Dental Company and changed its name to Patterson Companies, Inc. in June 2004. Patterson Companies, Inc. was founded in 1877 and is headquartered in Saint Paul, Minnesota.